Pipeline Discoveries for Autoimmune Diseases and Chronic Inflammation

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with autoimmune diseases and chronic inflammation. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

Inflammation Immunology Pipeline & Trials

Immunology Pipeline as of July 29, 2019

Download Complete Pipeline PDF

Discovery Projects
Phase 1

4
Phase 2

19
Phase 3

3
Registration

3
Total29

Compound Name	Indication	Phase	Submission Type	Compound Type
crisaborole (PF-06940799) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: PDE4 Inhibitor Go to clinical trial	Atopic Dermatitis (E.U.)	Registration	New Molecular Entity	Small Molecule
PF-06410293, a potential biosimilar to Humira� (adalimumab) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Biosimilar Business Segment: Biopharma Mechanism of Action: Tumor Necrosis Factor Inhibitor Go to clinical trial	Rheumatoid Arthritis (Biosimilar) (U.S. / E.U.)	Registration	Biosimilar	Biosimilar
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Registration Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor Go to clinical trial	Modified Release 11mg Tablet for Rheumatoid Arthritis (E.U.)	Registration	Product Enhancement	Small Molecule
abrocitinib (PF-04965842) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor Go to clinical trial	Atopic Dermatitis (BREAKTHROUGH)	Phase 3	New Molecular Entity	Small Molecule
PF-06651600 Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Go to clinical trial	Alopecia Areata (BREAKTHROUGH)	Phase 3	New Molecular Entity	Small Molecule
Xeljanz (tofacitinib) Therapeutic Area: Inflammation & Immunology Phase:Phase 3 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK Inhibitor Go to clinical trial	Ankylosing Spondylitis	Phase 3	Product Enhancement	Small Molecule
Dekavil Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: IL-10 Go to clinical trial	Rheumatoid Arthritis (Biologic)	Phase 2	New Molecular Entity	Biologic
Dekavil Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: IL-10 Go to clinical trial	Inflammatory Bowel Disease (Biologic)	Phase 2	Product Enhancement	Biologic
PF-06480605 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Biologic Business Segment: WRDM Mechanism of Action: TNFSF15 Blocker Go to clinical trial	Ulcerative Colitis (Biologic)	Phase 2	New Molecular Entity	Biologic
PF-06650833 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: IRAK4 Go to clinical trial	Rheumatoid Arthritis	Phase 2	New Molecular Entity	Small Molecule
PF-06651600 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Go to clinical trial	Rheumatoid Arthritis	Phase 2	Product Enhancement	Small Molecule
PF-06651600 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Go to clinical trial	Ulcerative Colitis	Phase 2	Product Enhancement	Small Molecule
PF-06651600 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Go to clinical trial	Crohn's Disease	Phase 2	Product Enhancement	Small Molecule
PF-06651600 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: Biopharma Mechanism of Action: JAK3/TEC Go to clinical trial	Vitiligo	Phase 2	Product Enhancement	Small Molecule
PF-06700841 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Go to clinical trial	Alopecia Areata	Phase 2	New Molecular Entity	Small Molecule
PF-06700841 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Go to clinical trial	Psoriasis	Phase 2	Product Enhancement	Small Molecule
PF-06700841 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Go to clinical trial	Ulcerative Colitis	Phase 2	Product Enhancement	Small Molecule
PF-06700841 Therapeutic Area: Inflammation & Immunology Phase:Phase 2 Compound Type:Small Molecule Business Segment: WRDM Mechanism of Action: TYK2/JAK1 Go to clinical trial	Crohn's Disease	Phase 2	Product Enhancement	Small Molecule